Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates Reactive Oxygen Species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner

Journal of Biological Chemistry

Volumn 287, Issue 26, 2012, Pages 22408-22417

  Cerna, David ^a   Li, Hongyun ^a   Flaherty, Siobhan ^a   Takebe, Naoko ^b   Coleman, C Norman ^b   Yoo, Stephen S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELLS; COLONY FORMATION; CYTOTOXIC; GLIOBLASTOMAS; HIGH FREQUENCY; NEUROBLASTOMAS; NICOTINIC ACID; NORMAL TISSUE; PHOSPHORIBOSYLTRANSFERASE; PRODUCTION INCREASE; RATE-LIMITING ENZYMES; REACTIVE OXYGEN SPECIES; SMALL MOLECULES; SPECIFIC INHIBITORS; SUPEROXIDES; THERAPEUTIC STRATEGY;

AMIDES; CELL DEATH; DISEASES; OXYGEN; TUMORS;

CYTOTOXICITY;

ANTIMYCIN A1; GMX 1778; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE 1; NICOTINIC ACID; PROTEIN INHIBITOR; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOMA; TREATMENT RESPONSE;

APOPTOSIS; CELL LINE, TUMOR; CYANIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; GUANIDINES; HUMANS; NADP; NIACINAMIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDATION-REDUCTION; PENTOSYLTRANSFERASES; REACTIVE OXYGEN SPECIES; SUPEROXIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862697493     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.357301     Document Type: Article

References (40)

1. Circu, M. L., and Aw, T. Y. (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 48, 749-762
2. Camhi, S. L., Lee, P., and Choi, A. M. (1995) The oxidative stress response. New Horiz. 3, 170-182
3. Martindale, J. L., and Holbrook, N. J. (2002) Cellular response to oxidative stress. Signaling for suicide and survival. J. Cell. Physiol. 192, 1-15
4. Thannickal, V. J., and Fanburg, B. L. (2000) Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L1005-L1028
5. Kuo, P. L., Chen, C. Y., and Hsu, Y. L. (2007) Isoobtusilactone A induces cell cycle arrest and apoptosis through reactive oxygen species/apoptosis signal-regulating kinase 1 signaling pathway in human breast cancer cells. Cancer Res. 67, 7406-7420
6. Meng, L. H., and Ding, J. (2007) Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol. Sin. 28, 1460-1465
7. Li, T. K., Chen, A. Y., Yu, C., Mao, Y., Wang, H., and Liu, L. F. (1999) Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress. Genes Dev. 13, 1553-1560
8. Wondrak, G. T. (2009) Redox-directed cancer therapeutics. Molecular mechanisms and opportunities. Antioxid. Redox. Signal. 11, 3013-3069
9. Kryston, T. B., Georgiev, A. B., Pissis, P., and Georgakilas, A. G. (2011) Role of oxidative stress andDNAdamage in human carcinogenesis. Mutat. Res. 711, 193-201
10. Maillet, A., and Pervaiz, S. (2012) Redox regulation of p53, redox effectors regulated by p53. A subtle balance. Antioxid. Redox. Signal. 16, 1285-1294
11. He, X., Ni, Y., Wang, Y., Romigh, T., and Eng, C. (2011) Naturally occurring germ line and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53. Hum. Mol. Genet. 20, 80-89
12. Szatrowski, T. P., and Nathan, C. F. (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51, 794-798
13. 2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem. J. 418, 29-37
14. Shi, X., Zhang, Y., Zheng, J., and Pan, J. (2012) Reactive oxygen species in cancer stem cells. Antioxid. Redox. Signal. 16, 1215-1228
15. Trachootham, D., Alexandre, J., and Huang, P. (2009) Targeting cancer cells by ROS-mediated mechanisms.Aradical therapeutic approach? Nat. Rev. Drug Discov. 8, 579-591
16. Raj, L., Ide, T., Gurkar, A. U., Foley, M., Schenone, M., Li, X., Tolliday, N. J., Golub, T. R., Carr, S. A., Shamji, A. F., Stern, A. M., Mandinova, A., Schreiber, S. L., and Lee, S. W. (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231-234
17. Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., and St Clair, D. K. (2007) Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol. Interv. 7, 147-156
18. Hara, N., Yamada, K., Shibata, T., Osago, H., Hashimoto, T., and Tsuchiya, M. (2007) Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J. Biol. Chem. 282, 24574-24582
19. Garten, A., Petzold, S., Körner, A., Imai, S., and Kiess, W. (2009) Nampt. LinkingNADbiology, metabolism, and cancer. Trends Endocrinol. Metab. 20, 130-138
20. Beauparlant, P., Bédard, D., Bernier, C., Chan, H., Gilbert, K., Goulet, D., Gratton, M. O., Lavoie, M., Roulston, A., Turcotte, E., and Watson, M. (2009) Preclinical development of the nicotinamide phosphoribosyltransferase inhibitor prodrug GMX1777. Anti-Cancer Drugs 20, 346-354
21. + biosynthesis. Strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell. Biol. 29, 5872-5888
22. Kato, H., Ito, E., Shi, W., Alajez, N. M., Yue, S., Lee, C., Chan, N., Bhogal, N., Coackley, C. L., Vines, D., Green, D., Waldron, J., Gullane, P., Bristow, R., and Liu, F. F. (2010) Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin. Cancer Res. 16, 898-911
23. Fuchs, D., Rodriguez, A., Eriksson, S., Christofferson, R., Sundberg, C., and Azarbayjani, F. (2010) Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance. Int. J. Cancer 126, 2773-2789
24. Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J. K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., Thomas, C. J., Vander Heiden, M. G., and Cantley, L. C. (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334, 1278-1283
25. Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009) Understanding the Warburg effect. The metabolic requirements of cell proliferation. Science 324, 1029-1033
26. Luo, J., Solimini, N. L., and Elledge, S. J. (2009) Principles of cancer therapy. Oncogene and nononcogene addiction. Cell 136, 823-837
27. Chen, X., Ko, L. J., Jayaraman, L., and Prives, C. (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438-2451
28. Kirsch, M., and De Groot, H. (2001) NAD(P)H, a directly operating antioxidant? FASEB J. 15, 1569-1574
29. Liu, B., Chen, Y., and St Clair, D. K. (2008) ROS and p53. A versatile partnership. Free Radic. Biol. Med. 44, 1529-1535
30. Simon, H. U., Haj-Yehia, A., and Levi-Schaffer, F. (2000) Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5, 415-418
31. Izeradjene, K., Douglas, L., Tillman, D. M., Delaney, A. B., and Houghton, J. A. (2005) Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res. 65, 7436-7445
32. Huang, H. L., Fang, L. W., Lu, S. P., Chou, C. K., Luh, T. Y., and Lai, M. Z. (2003) DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation. Oncogene 22, 8168-8177
33. Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., and Chumakov, P. M. (2005) The antioxidant function of the p53 tumor suppressor. Nat. Med. 11, 1306-1313
34. Das, S., Raj, L., Zhao, B., Kimura, Y., Bernstein, A., Aaronson, S. A., and Lee, S. W. (2007) Hzf determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 130, 624-637
35. Sen, N., Satija, Y. K., and Das, S. (2011) PGC-1α, a key modulator of p53, promotes cell survival upon metabolic stress. Mol. Cell 44, 621-634
36. Tanaka, T., Ohkubo, S., Tatsuno, I., and Prives, C. (2007) hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 130, 638-650
37. Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., West- brook, T. F., Wong, K. K., and Elledge, S. J. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848
38. Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., and Helleday, T. (2005) Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917
39. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C., and Ashworth, A. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921
40. Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., Joshua, B., Kaplan, M. J., Wapnir, I., Dirbas, F. M., Somlo, G., Garberoglio, C., Paz, B., Shen, J., Lau, S. K., Quake, S. R., Brown, J. M., Weissman, I. L., and Clarke, M. F. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780-783